COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

NCT04452318 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3303

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: REGN10933 + REGN10987
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals